LSE GBp

AstraZeneca PLC (AZN.L)

10,982.00

-6.00

(-0.05%)

At close: January 10 at 5:42:34 PM GMT

3 Cheap Growth Stocks to Buy in 2025

As we enter 2025, many growth stocks are trading at high valuations and could be running out of room to rise in the near term. For long-term investors, now may be a good time to reevaluate the contents of your portfolio to see if it's worth potentially selling off some of your recent high performers and swapping in some cheaper growth stocks instead. Three growth stocks that look particularly cheap right now are AstraZeneca (NASDAQ: AZN), Uber Technologies (NYSE: UBER), and Zoom Communications (NASDAQ: ZM).

Motley Fool 2 days ago

AZN

ZM

UBER
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.

Zacks 3 days ago

AZN
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 3 days ago

AZN
Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?

We recently compiled a list of the 10 Best FTSE Dividend Stocks To Buy Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other FTSE dividend stocks. Goldman Sachs Research predicts moderate growth for the UK economy in 2025, with GDP rising 1.2%. That is slightly […]

Insider Monkey 5 days ago

AZN

^FTSE
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.

Zacks 5 days ago

AZN
Better Buy: Novo Nordisk vs. AstraZeneca

Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn't know it by looking at their stock market performances. AstraZeneca's shares are down by 2% over the trailing-12-month period, while Novo Nordisk's shares are in the red by 14%.

Motley Fool 7 days ago

NVO

AZN
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review

HUTCHMED is set to gain a milestone payment from AstraZeneca.

Pharmaceutical Technology 8 days ago

AZN
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.

Zacks 8 days ago

ABBV

AZN

PFE
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.

Zacks 9 days ago

MNPR

AZN

CSTL
5 Large Drug Stocks to Keep An Eye On in the New Year

R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.

Zacks 9 days ago

PFE

ABBV

AZN
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?

We recently compiled a list of the U.K. Dividend Champions List: 2024 Rankings by Yield. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other U.K. dividend champions. In recent years, investors have shown a preference for global stocks, particularly high-growth options like US technology companies, over […]

Insider Monkey 12 days ago

AZN

^FTSE
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?

We recently compiled a list of the U.K. Dividend Aristocrats List: 2024 Rankings by Yield. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other U.K. dividend aristocrats. In recent years, investors have turned away from UK equities, opting instead for global stocks, particularly high-growth options like […]

Insider Monkey 13 days ago

AZN

^FTSE
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know

The latest trading day saw Astrazeneca (AZN) settling at $66.26, representing a -0.39% change from its previous close.

Zacks 15 days ago

AZN
Here's Why Astrazeneca (AZN) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 15 days ago

AZN
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.

Zacks 16 days ago

AZN

4568.T

PFE
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment

The application for Dato-DXd was supported by results from the Phase III TROPION-Lung01 clinical trial.

Pharmaceutical Technology 16 days ago

4568.T

AZN
AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

AstraZeneca PLC ( LON:AZN ) shareholders might be concerned after seeing the share price drop 11% in the last quarter...

Simply Wall St. 16 days ago

AZN

AZNCF
Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Cancer study to AstraZeneca (AZN). TRACERx, led by Professor Charles Swanton at University College London, UK, is one of the largest tumor evolution studies to generate deep sequencing multi-region and multi-time-point genetic data from over 3,200 tumor samples from over 800 lung cancer patients. As part of the transaction, AstraZeneca will also take over

TipRanks 17 days ago

AZN

AZNCF

ACHL
AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) have voluntarily withdrawn the marketing authorization application in the EU for datopotamab deruxtecan for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer based on the TROPION-Lung01 Phase 3 trial, the companies announced. “The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency. AstraZeneca and Daiichi

TipRanks 17 days ago

AZN

AZNCF
AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

The approval was based on the outcomes from the Phase III LAURA trial.

Pharmaceutical Technology 18 days ago

AZN

Performance Overview

Return	AZN.L	FTSE 100
YTD	+5.51%	+1.57%
1-Year	+2.94%	+7.35%
3-Year	+39.64%	+10.20%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AstraZeneca PLC (AZN.L)

3 Cheap Growth Stocks to Buy in 2025

Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know

Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term

Why Is AstraZeneca PLC (NASDAQ:AZN) Among the Best FTSE Dividend Stocks to Buy Now?

AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?

Better Buy: Novo Nordisk vs. AstraZeneca

China’s NMPA prioritises HUTCHMED’s lung cancer therapy review

The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

5 Large Drug Stocks to Keep An Eye On in the New Year

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?

Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?

Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know

Here's Why Astrazeneca (AZN) is a Strong Value Stock

AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC

AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment

AstraZeneca's (LON:AZN) investors will be pleased with their respectable 55% return over the last five years

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

AstraZeneca, Daiichi Sankyo have voluntarily withdrawn a Dato-DXd MAA in EU

AstraZeneca’s Tagrisso gains EC approval for NSCLC treatment

Performance Overview